Figure 1
Figure 1. Analysis of RAS mutation and Akt activation in primary MM samples. (A) RAS mutation status and sensitivity to Akt blockade in freshly isolated primary MM cells (n = 25). Viability measurements of MM cells cocultured with bone marrow stromal cells were performed after 5-day treatment with 10μM Akti-1,2. Sensitivity to Akt inhibition shows no obvious correlation with the presence or absence of RAS mutation. Medians are indicated. (B) Correlation between Akti-1,2 (10μM) sensitivity of freshly isolated, cocultured primary MM cells and the presence or absence of phospho-Akt in immunohistochemical stains of matched bone marrow biopsies (n = 19). Phospho-Akt positivity in the biopsies was significantly (P < .05) correlated with sensitivity to Akt inhibition of the respective MM cells. (C) RAS mutation in primary MM cells and phospho-Akt status in corresponding bone marrow biopsies (n = 59). RAS mutations were present in 16 of 34 phospho-Akt-positive and in 8 of 25 phospho-Akt-negative samples. (D) Two examples of MM patient biopsies with immunofluorescent double staining for plasma-cell marker CD138 (green) and either phospho-Akt Ser473 or phospho-Akt Thr308 (both in red). A phospho-Akt-negative (patient 6) and a phospho-Akt-positive (patient 20) sample are shown. Bar represents 75 μm.

Analysis of RAS mutation and Akt activation in primary MM samples. (A) RAS mutation status and sensitivity to Akt blockade in freshly isolated primary MM cells (n = 25). Viability measurements of MM cells cocultured with bone marrow stromal cells were performed after 5-day treatment with 10μM Akti-1,2. Sensitivity to Akt inhibition shows no obvious correlation with the presence or absence of RAS mutation. Medians are indicated. (B) Correlation between Akti-1,2 (10μM) sensitivity of freshly isolated, cocultured primary MM cells and the presence or absence of phospho-Akt in immunohistochemical stains of matched bone marrow biopsies (n = 19). Phospho-Akt positivity in the biopsies was significantly (P < .05) correlated with sensitivity to Akt inhibition of the respective MM cells. (C) RAS mutation in primary MM cells and phospho-Akt status in corresponding bone marrow biopsies (n = 59). RAS mutations were present in 16 of 34 phospho-Akt-positive and in 8 of 25 phospho-Akt-negative samples. (D) Two examples of MM patient biopsies with immunofluorescent double staining for plasma-cell marker CD138 (green) and either phospho-Akt Ser473 or phospho-Akt Thr308 (both in red). A phospho-Akt-negative (patient 6) and a phospho-Akt-positive (patient 20) sample are shown. Bar represents 75 μm.

Close Modal

or Create an Account

Close Modal
Close Modal